v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A preferred stock
Preferred Stock
Series A-2 Preferred Stock
Preferred Stock
Series A-3 Preferred Stock
Preferred Stock
Series CF Preferred Stock
Preferred Stock
Series B Preferred Stock [Member]
Preferred Stock
Series A Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717   6,642      
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 0 $ 1 $ 27,482,060 $ (33,345,997) $ (5,857,645)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075)   $ 4 6,287   6,291
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717)   40,272      
Issuance of common stock in public offering               $ 2 10,000,000   10,000,002
Issuance of common stock in public offering (in shares)               24,096      
Offering costs                 (2,116,957)   (2,116,957)
Exercise of over-allotment option, net of offering costs                 1,364,997   1,364,997
Exercise of over-allotment option, net of offering costs (in shares)               3,614      
Conversion of debt into common stock               $ 1 2,680,288   2,680,289
Conversion of debt into common stock (In shares)               11,352      
Conversion of related party notes and payables into common stock                 257,515   257,515
Conversion of related party notes and payables into common stock (in shares)               1,524      
Common stock issued in connection with business combination               $ 3 11,428,735   11,428,738
Common stock issued in connection with business combination (in shares)               32,943      
Exercise of warrants                 1,768,046   1,768,046
Exercise of warrants (in shares)               3,869      
Common stock issued pursuant to consulting agreement                 595,500   595,500
Common stock issued pursuant to consulting agreement (in shares)               2,415      
Issuance of common stock pursuant to equity line of credit                 367,696   367,696
Issuance of common stock pursuant to equity line of credit (in shares)               1,264      
Common stock and warrants issued in connection with notes                 501,658   501,658
Common stock and warrants issued in connection with notes (in shares)               1,300      
Stock-based compensation                 4,278,337   4,278,337
Stock-based compensation (Shares)               727      
Net loss                   (32,357,957) (32,357,957)
Ending balance at Dec. 31, 2021               $ 13 58,614,160 (65,703,954) (7,089,781)
Ending balance (in shares) at Dec. 31, 2021               130,018      
Issuance of common stock in public offering               $ 37 9,347,413   9,347,450
Issuance of common stock in public offering (in shares)               373,898      
Issuance of common stock and exercise of pre-funded warrants in public offering (in shares)               1,818,181      
Issuance of common stock and exercise of pre-funded warrants in public offering               $ 182 9,999,814   9,999,996
Offering costs                 (2,921,646)   (2,921,646)
Common stock issued in connection with business combination               $ 9 999,991   1,000,000
Common stock issued in connection with business combination (in shares)               90,909      
Common stock issued pursuant to consulting agreement                 123,000   123,000
Common stock issued pursuant to consulting agreement (in shares)               750      
Stock-based compensation                 479,038   479,038
Net loss                   (38,043,362) (38,043,362)
Conversion of notes and derivative liability into common stock               $ 200 11,983,189   11,983,389
Conversion of notes and derivative liability into common stock (in shares)               1,995,183      
Warrant and common shares issued with notes               $ 6 1,368,735   1,368,741
Warrant and common shares issued with notes (in shares)               60,000      
Conversion of venture debt into Series A convertible preferred stock             $ 1   6,299,999   6,300,000
Conversion of venture debt into Series A convertible preferred stock (in shares)             6,300        
Ending balance at Dec. 31, 2022             $ 1 $ 447 $ 96,293,694 $ (103,747,316) $ (7,453,174)
Ending balance (in shares) at Dec. 31, 2022               4,468,939